FHLC vs. XLV: Broader Health Care Exposure or Deeper Liquidity
FHLC owns hundreds of health care companies across market sizes, while XLV concentrates on large S&P 500 names. The choice is mainly about breadth, concentration and trading liquidity, not a proven return advantage.
FHLC and XLV both offer low-cost exposure to U.S. health care, but they own different versions of the sector. Fidelity's FHLC reaches into mid-cap and small-cap companies, while State Street's XLV is limited to health care members of the S&P 500. The practical trade-off is breadth versus liquidity and large-cap concentration.
Fidelity listed 350 basket holdings for FHLC as of September 30, 2026. Its largest positions included Eli Lilly at 12.94% and Johnson & Johnson at 8.90%, for a combined 21.84%. The fund also held smaller biotechnology companies, device makers and diagnostics businesses that do not qualify for the S&P 500.
XLV was more concentrated. State Street reported Eli Lilly at 15.66% and Johnson & Johnson at 9.77% as of October 23, a combined 25.43%. The portfolio's industry mix included 36.43% in pharmaceuticals, 19.70% in biotechnology and 17.59% in health care providers and services.
That difference does not mean FHLC is automatically more diversified in every sense. Hundreds of tiny positions may have little effect on total returns, while broader exposure to early-stage biotechnology can introduce clinical, financing and dilution risk. XLV's large-cap construction reduces those small-company risks but leaves more of the portfolio dependent on a handful of dominant companies.
Costs are nearly identical. Fidelity reported an expense ratio of 0.084% for FHLC, while State Street listed 0.08% for XLV. On a $10,000 investment, the difference is less than one dollar a year before trading costs. Investors should therefore focus more on portfolio construction and liquidity than on the fee gap.
Liquidity is XLV's clearest advantage. State Street reported roughly $47.3 billion of assets as of October 28, far above FHLC's approximately $3.2 billion reported by Fidelity in June. A larger asset base and heavier trading usually support tighter bid-ask spreads, which matters most to frequent traders or investors placing large orders.
FHLC may suit long-term investors who want the whole listed health care market and accept small-company volatility. XLV may suit investors who want a liquid sector allocation centered on established companies. Neither structure guarantees better performance.
The selection should be reviewed as holdings change. Investors should compare current concentration, spreads and tax consequences before switching funds. The evidence supports a structural distinction, not a claim that one ETF will outperform the other.